Clinical Trials Logo

Rocuronium clinical trials

View clinical trials related to Rocuronium.

Filter by:

NCT ID: NCT05515835 Enrolling by invitation - Body Composition Clinical Trials

Relationship Between Effect Duration of Rocuronium and Body Composition Analysis Data.

Start date: September 5, 2022
Phase:
Study type: Observational

The induction dose of rocuronium is typically decided based on the patient's body weight, but the effect duration of rocuronium is variable. Some studies suggest that body composition analysis data, such as skeletal muscle mass or total body water, may correlate better with the duration time of rocuronium. Therefore, we plan to analyse body composition in patients undergoing total intravenous general anesthesia, give the patients a fixed dose (50mg) of rocuronium, and check the correlation between duration time of rocuronium and body composition analysis data.

NCT ID: NCT05476952 Completed - Body Weight Changes Clinical Trials

Lean Body Weight-adjusted Rocuronium Dose and Intubation Conditions

LBW
Start date: January 30, 2023
Phase:
Study type: Observational

In this study, researchers wiil administer rocuronium, based on either the lean body weight or the total body weight in patients with body mass index (BMI) of 18.5 to 34.9 and compared the duration of action of the drug and its effects on tracheal intubation conditions and hemodynamic parameters..

NCT ID: NCT05343702 Completed - Rocuronium Clinical Trials

Comparison of Standard rapi̇d Sequential Intubation Protocol With Rocuronium in Emergency Department

Start date: July 15, 2021
Phase:
Study type: Observational [Patient Registry]

Airway management and advanced airway management are the issues that are applied every day in emergency services and that the emergency physician should know best. Rapid sequential intubation is one of the most frequently used techniques in advanced airway management. However, anesthetic agents and paralytic agents have some concerns with some side effects. In our study, This study aimed to compare the effect of standard rapid sequential intubation protocol and application of rocuronium priming technique on the procedure time and hemodynamic profile.

NCT ID: NCT05217238 Recruiting - Rocuronium Clinical Trials

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium

Start date: December 18, 2021
Phase: N/A
Study type: Interventional

As a medium-and long-term non-depolarizing muscle relaxant, rocuronium has the advantages of quick effect, no histamine release and accumulation and no obvious cardiovascular adverse reactions, so it has been widely used in clinical anesthesia induction. However, when given intravenously, rocuronium can cause adverse reactions such as injection pain and limb retraction, which can lead to needle prolapse, extravasation of injection drugs, swelling of injection site, serious induction delay, and cardiovascular adverse events in severe cases. Remifentanil is a synthetic opioid drug hydrolyzed by esterase. Compared with other opioid drugs, remifentanil has the advantages of quick effect, short half-life and short time of hemodynamic changes, so it is an ideal analgesic in clinical anesthesia. In this study, in order to provide clinical references, sequential method was used to find the median effective dose (ED50) by means of pre-intravenous injection of Remifentanil to suppress pain in rocuronium injection.

NCT ID: NCT05067829 Not yet recruiting - Rocuronium Clinical Trials

Rapid Sequence Intubation With Rocuronium in Elderly Patients

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

With the prolongation of life expectancy, the frequency of surgical intervention and anesthesia increases in elderly patients. The rapid Sequence Intubation(RSI) technique is preferred in patients with aspiration risk and who will undergo general anesthesia, especially in the pandemic period, to reduce or eliminate the aerosolization of respiratory secretions. The use of rocuronium at a dose of 1 mg/kg in RSI also causes prolongation of the recovery of neuromuscular block. This study aimed to compare the intubation conditions and train-of-four count(TOFC) 1-2 times of the rocuronium doses with priming according to ideal body weight(IBW), corrected body weight(CBW), and total body weight(TBW) in RSI of patients aged >65 years.

NCT ID: NCT05066035 Completed - Clinical trials for Neuromuscular Blockade

Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

Start date: May 1, 2013
Phase: Phase 4
Study type: Interventional

Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end of the operation. Our goal is to compare the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine to the routine use of reversal medication.

NCT ID: NCT05028088 Recruiting - Liver Dysfunction Clinical Trials

Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex

Start date: July 1, 2021
Phase: Phase 4
Study type: Interventional

The use of muscle relaxants is an indispensable in the general anesthesia but is prone to accidents, which are often related to residual muscle relaxant. Therefore, how to timely and effectively eliminate the residual effect of muscle relaxants after surgery has become an urgent clinical problem. Rocuronium is a non-depolarizing muscle relaxant that is primarily metabolized by the liver. Patients with liver dysfunction can affect the metabolic process of rocuronium, thereby delaying the recovery of muscle relaxation. Sugammadex (SUG) is a novel specific antagonist of aminosteroid muscle relaxants, which can effectively antagonize muscle relaxants at different depths. However, whether liver dysfunction affects the antagonistic effect of SUG against rocuronium has not been reported yet. Therefore, the investigators hypothesize that with the increase of patients' liver Child-Pugh grade, the recovery time of rocuronium antagonized by the same dose of SUG after surgery will be prolonged, and the incidence of muscle relaxation residual will be increased in the short term.

NCT ID: NCT04821817 Recruiting - Strabismus Clinical Trials

Peribulbar Rocuronium in Adult Strabismus Surgery

Start date: April 3, 2021
Phase: N/A
Study type: Interventional

- This is a prospective randomized clinical study that will be carried on adult patients aged from 21-60 years and presented for strabismus surgery under peribulbar anesthesia. - Patients will be excluded if they refused to participate or had a contraindication to peribulbar anesthesia. - Patients will be randomly distributed into either control group in which peribulbar anesthesia will be performed by injection of 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline or rocuronium group which peribulbar anesthesia will be performed by injection of 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline. - Measurements will include; - 1. Patient age, weight, height, gestational age, and gravidity. 2. The duration of globe akinesia (primary outcome). 3. The onset of lid and globe akinesia and the duration of lid akinesia 4. The onset and duration of sensory block 5. Time required to start the surgery 6. Akinesia score 7. The visual analog score (VAS) which is composed of 0-10 score will be used to assess the severity of postoperative pain (where 0=no pain and 10=severe pain), The VAS score will be evaluated 1 h, 2 h postoperative, then every 2 h till 12 h. Any patients with VAS score more than 4 received rescue analgesia in the form of 50 mg tramadol intravenous injection with the calculation of the time for the first call of postoperative analgesia. 8. Any detected complication as nausea and vomiting, pain on injection, or increased intraocular tension.

NCT ID: NCT04760912 Enrolling by invitation - Muscle Weakness Clinical Trials

General Anesthesia With and Without Muscle Relaxation and Muscle Strength Recovery

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

Neuromuscular blocking agents are often used during general anesthesia. Also, general anesthesia may be performed without use of neuromuscular blocking agents. Avoiding neuromuscular relaxation enables better muscle strength recovery.

NCT ID: NCT04236050 Completed - Recovery Clinical Trials

Continuous Infusion and Bolus Doses of Rocuronium During Lumbal Discectomy, Muscle Strength and Patient Recovery

Start date: December 2015
Phase: N/A
Study type: Interventional

The continuous infusion of rocuronium during general anesthesia for a lumbar discectomy enables better muscle strength recovery, and a better quality of patient recovery as measured by questionnaire.